PropertyValue
?:definition
  • The unique identifier assigned to the arm of the Molecular Analysis for Therapy Choice (MATCH) phase II clinical trial that is investigating treatment with capivasertib in patients with cancers that have AKT gene mutations.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
expand all